Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jul 30, 2008

166_ip_2008-07-30_7d5e9016-97e0-4e59-87ac-770b502d1efa.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Analyst Meeting – H1/08 Results

July 30, 2008

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forwardlooking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

ADDITIONAL INFORMATION

In connection with Fresenius Kabi Pharmaceuticals Holding, LLC's proposed acquisition of APP Pharmaceuticals, Inc., Fresenius Kabi Pharmaceuticals Holding, LLC and APP Pharmaceuticals, Inc. will file relevant materials with the SEC, including a registration statement that will contain a joint prospectus and information statement. Investors and security holders are urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they will contain important information. Investors and security holders may obtain these documents free of charge at the SEC's website at www.sec.gov. Such documents are not currently available. Investors and security holders are urged to read the joint information statement/prospectus and the other relevant materials when they become available before making any investment decision with respect to the proposed acquisition.

Fresenius Group: Financial Results

S
l
a
e
s		 E
B
I
T		 i
N
t
e
n
c
o
m
e
/
0
8
H
1		 €
0
5
7
1
m
,		 €
8
7
1
m		 €
2
1
2
m
G
h
t
t
t
t
o
a
c
o
n
s
a
n
r
w
t
c
e
n
c
a
e
s
u
r
r
y
r		 9
%		 8
%		 1
4
%
h
l
G
t
t
t
r
o
w
a
a
c
u
a
t
c
u
r
r
e
n
c
y
r
a
e
s		 2
%		 0
%		 9
%

Fresenius Group: Double-digit Sales Growth in all Business Segments

/
H
1
0
8		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
l
S
a
e
s
h
G
t
r
o
w		 \$
U
S
5
1
7
7
m
,
1
0
%		 €
1
1
2
1
m
,
%
1
4		 €
1
0
0
4
m
,
%
1
7		 €
1
7
7
m
%
1
1
E
B
I
T
h
G
t
r
o
w		 \$
S
8
8
U
1
m
8
%		 8
€
1
1
m
1
4
%		 8
€
3
m
2
2
%		 €
9
m
0
%

Fresenius Kabi: Update H1/08

  • Excellent organic sales growth of 10 %
  • Performance of 2007 acquisitions fully in line with our expectations
  • Dabur Pharma: Successful conclusion of public offer allows for transaction closing in Q3/08
  • APP outstanding opportunity to achieve a leading position in i.v. drugs and to grow Fresenius Kabi´s existing product portfolio in the U.S.

APP Pharmaceuticals – Transaction Update

  • Financing package
  • first step of equity financing put in place
  • will not limit growth opportunities in other business segments
  • FTC filing submitted
  • Integration planning initiated
  • complementary structures →virtually no overlap
  • very strong cultural fit, strong leadership team
    • Confirm EPS* neutral in year 1 after closing, clearly accretive in year 2
  • no cross-selling revenue synergies included
  • update with bottom-up synergy opportunities and timelines in H1/2009

Conference Call – Results H1/2008, Fresenius SE, Investor Relations © Copyright, July 30, 2008 Page 6 * EPS: before one-time transaction-related depreciation charges and assuming a 2008 closing.

Fresenius Helios: Update H1/08

  • Strong organic revenue growth of 5 %*
  • 1.8 % EBIT margin progression in established clinics
  • Smooth integration of Krefeld/Hüls hospitals
  • ~9 % increase in hospital admissions
  • Krefeld hospital construction plans finalized; investment of ~ € 180 m until 2015

Fresenius Vamed: Update H1/08

    • H1/08 financial results fully on track to meet 2008 guidance
    • Strong order intake in H1/08
    • € 25 m awarded for the hospital extension in Oberndorf/Austria
    • € 8 m for medical technical equipment supply for 25 hospitals in Sri Lanka
    • Hermed acquisition on track – perfect fit to strengthen the German service business

Group Financials H1/08 −Outlook 2008

Fresenius Group: Profit and Loss Statement

€
m		 /
Q
8
2
0		 /
H
8
1
0		 /
H
8
1
0
l
t
a
c
a
u
t
r
a
e
s		 Y
Y
o
t
t
c
o
n
s
a
n
t
r
a
e
s		 R
k
e
m
a
r
s
l
S
a
e
s		 2
9
1
2
,		 5
7
1
0
,		 2
%		 9
%		 O
i
h
6
%
t
r
g
a
n
c
g
r
o
w
:
E
B
I
T		 0
4
4		 8
1
7		 0
%		 8
%		 3.
%
M
i
1
7
a
r
g
n
:
l
I
t
t
t
n
e
e
s
e
s
r
r
u		 8
3
-		 6
1
7
-		 0
%
1		 2
%		 P
i
i
t
o
s
e
c
e
n
c
v
u
r
r
y
i
l
t,
m
p
a
c
o
w
e
r
a
v
e
r
a
g
e
t
a
e
s
r
T
a
e
s
x		 1
1
1
-		 2
1
4
-		 0
%		 8
%
-		 3
9
T
t
4
%
a
a
e
x
r
:
N
i
t
e
n
o
m
e
c		 2
1
1		 2
2
1		 9
%		 %
1
4

Fresenius Kabi: Organic Sales Growth of 10 %

€
m		 /
H
0
8
1		 /
H
0
1
7		 C
h
a
n
g
e		 O
i
r
g
a
n
c
G
h
t
r
o
w
G
e
m
a
n
r
y		 2
1
3		 2
1
3		 0
%		 2
%
E
u
r
o
p
e
G
e
e
m
a
n
x
r
y		 3
6
5		 6
4
1		 6
%
1		 %
7
f
A
i
P
i
i
s
a
a
c
c
-		 1
8
0		 1
4
5		 2
4
%		 2
7
%
i
i
L
A
t
a
n
m
e
c
a
r		 8
4		 6
6		 2
%
7		 9
%
R
W
o		 1
0
8		 1
0
1		 7
%		 1
1
%
l
l
T
t
o
a
s
a
e
s		 1
1
2
1
,		 9
8
6		 1
4
%		 1
0
%

Fresenius Kabi: Strong EBIT Growth

€
m		 /
H
1
0
8		 /
H
1
0
7		 G
h
t
r
o
w
T
l
E
B
I
T
t
o
a
M
i
a
r
g
n		 1
8
1
6
%
1
1		 1
5
9
6
%
1
1		 1
4
%
i
B
R
y
e
g
o
n
:
E
o
p
e
u
r
M
i
a
g
n
r		 1
6
2
2
1.
6
%		 1
4
5
2
1.
5
%		 1
2
%
l
I
i
t
t
n
e
r
n
a
o
n
a
M
i
a
r
g
n		 6
0
1
6.
1
%		 0
5
1
6.
0
%		 2
0
%
d
C
C
R
&
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 4
1
-		 3
6
-		 1
4
%
-

Fresenius Group: Cash Flow

€
m		 /
Q
2
0
8		 /
H
1
0
8		 Y
Y
o		 R
k
e
m
a
r
s
C
h
f
l
a
s
o
w		 3
2
4		 6
2
4		 %
7		 S
h
t
i
t
r
o
n
g
e
a
r
n
n
g
s
g
r
o
w
h
k
l
C
i
i
i
t
a
n
g
e
n
o
n
g
c
a
p
a
w
r		 1
2
1
-		 1
4
3
-		 --
O
i
C
h
f
l
t
p
e
r
a
n
g
a
s
o
w		 2
0
3		 4
8
1		 1
3
%
-		 i
8
%
M
4
a
r
g
n
:
C
(
)
t
a
p
e
x
n
e		 1
7
1
-		 3
3
2
-		 1
3
%
-		 k
f
f
l
l-
O
t
n
a
c
o
e
a
r
r
u
y
r
C
h
f
l
a
s
o
w
f.
(
b
i
i
i
d
d
i
i
d
d
)
t
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 3
2		 1
4
9		 4
2
%
-		 d
i
g
a
n
c
e
u
i
i
i
A
t
(
)
t
c
q
u
s
o
n
s
n
e		 6
5
-		 2
2
4
-		 3
%
7
-
d
d
D
i
i
v
e
n
s		 2
1
3
-		 2
1
8
-		 1
6
%
-
h
f
l
F
C
e
e
a
s
o
r
w
(
f
d
d
d
d
)
t
i
i
t
i
i
i
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 2
4
6
-		 2
9
3
-		 --

Fresenius Business Segments: Financial Outlook 2008 Fully Confirmed

b
F
i
K
i
r
e
s
e
n
u
s
a		 l
h
(
)
S
t
a
e
s
g
r
o
w
c
c
E
B
I
T
i
m
a
r
g
n		 1
2
1
5
%
–
1
6
5
%
~
l
F
i
H
i
e
s
e
n
s
e
o
s
r
u		 l
S
a
e
s
E
B
I
T		 €
2
0
5
0
>
m
,
€
1
6
0
1
0
7
m
–
d
F
i
V
e
e
n
m
e
r
s
u
s
a		 S
l
h
t
e
g
o
a
s
r
w
h
E
B
I
T
t
g
r
o
w		 0
%
5
1
–
0
%
5
1
–
h
F
i
B
i
t
r
e
s
e
n
u
s
o
e
c		 E
B
I
T		 €
5
0
m
~
-

Fresenius Group: Outlook 2008 Fully Confirmed

h
R
t
e
e
n
e
g
o
v
u
r
w
i
t
t
n
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 8
0
%
1
-
h
N
i
t
t
e
n
o
m
e
g
o
c
r
w
i
t
t
n
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 0
1
1
5
%
-
C
a
p
e
x		 €
0
7
5
m
~

APP Acquisition Financing: Execution Fully on Track

  • Impact on credit ratings minimized
  • Long-term financing components:

Equity

d
h
b
l
b
d
M
t
a
n
a
o
e
c
a
n
g
e
a
e
o
n
s
r
y
x
-		 €
5
5
4
m
l
l
P
i
i
i
t
t
t
o
e
n
p
n
e
e
a
c
a
a
c
r
a
s
-		 3
0
0
€
t
p
o
m
u
b
D
t
e
d
d
l
S
i
t
y
n
c
a
e
o
a
n
-		 \$
2
4
0
0
m
,		 i
n
p
r
o
c
e
s
s
d
b
i
i
V
t
t
t
a
o
s
e
n
s
m
e
n
s
r
u
r
u
-		 d
l
f
i
i
i
e
s
a
n
a
n
c
n
g
r
u

Attachments

Fresenius Group:

Overview – Calculation of Minority Interest

€
m		 /
H
1
0
8		 /
F
Y
0
7
f
b
d
E
i
i
i
i
t
t
t
t
a
n
n
g
s
e
o
e
a
a
n
m
n
o
n
e
e
s
r
r
x
r
y
r		 6
1
4		 2
1
4
1
,
T
a
e
s
x		 2
1
4
-		 4
4
8
-
h
f
M
i
i
i
t
t
t,
t
n
o
r
y
n
e
r
e
s
e
r
e
o		 8
8
1
-		 3
8
3
-
d
l
b
b
l
F
i
M
i
C
i
i
t
t
t
t
t
e
s
e
n
s
e
a
a
e
n
e
n
o
m
e
n
o
a
a
e
r
u
c
r
c
r
u
(
)
F
i
6
4
%
t
o
e
s
e
n
s
r
u
~		 1
6
6
-		 3
3
5
-
h
l
d
d
l
M
i
i
i
i
F
i
M
i
C
t
t
t
n
o
n
e
e
s
o
e
s
n
e
s
e
n
s
e
c
a
a
e
r
y
r
r
r
u
r
(
/
\$
/
\$
d
F
Y
2
0
0
7
U
S
2
6
H
1
2
0
0
8
U
S
1
3
i
m
m
a
c
c
o
n
g
:
:
r
,
d
l
C
's
l
S
)
t
F
i
M
i
F
i
i
t
t
t
o
r
e
s
e
n
u
s
e
c
a
a
r
e
n
a
n
c
a
a
e
m
e
n
s		 8
-		 1
9
-
h
l
d
b
M
i
i
i
i
F
i
K
i,
t
t
t
n
o
r
y
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
a
l
h
d
d
F
i
H
i
F
i
B
i
t
t
r
e
s
e
n
u
s
e
o
s,
r
e
s
e
n
u
s
o
e
c
a
n
u
e
o
d
's
l
h
F
i
V
2
3
%
i
t
e
s
e
n
s
a
m
e
e
e
n
a
o
n
e
s
p
r
u
x
r
w
r		 1
4
-		 2
9
-
i
N
t
e
n
c
o
m
e		 2
1
2		 1
0
4

Fresenius Group: Debt and Interest Ratios

Fresenius Helios: Outstanding Sales Growth

€
m		 /
H
1
0
8		 /
H
1
0
7		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 0
0
1
4
,		 8
9
0		 %
1
7
f
b
l
i
h
d
l
i
i
l
i
t
t
e
s
a
s
e
c
n
c
p
o
r
o
o
-
(
l
d
)
i
i
i
i
i
1
t
t
<
a
c
q
s
o
n
s
c
o
n
s
o
a
o
n
u
y
r
-		 9
4
5
9
5		 8
9
0
0		 *
%
5

* growth rate on a like for like basis

Fresenius Helios: Excellent Earnings Development

€
m		 /
H
1
0
8		 /
H
1
0
7		 G
h
t
r
o
w
T
l
E
B
I
T
t
o
a
i
M
a
r
g
n		 8
3
8
0
%		 6
8
6
%
7		 2
2
%
f
b
l
i
h
d
l
i
i
l
i
t
t
e
e
n
p
o
o
o
s
a
s
c
c
r
-
M
i
a
r
g
n
i
i
i
t
(
l
i
d
i
1
)
t
a
c
q
s
o
n
s
u
<
c
o
n
s
o
a
o
n
y
r
-		 8
9
9
%
4
6
-		 6
8
6
%
7.
0

Fresenius Vamed: Strong Sales Development

€
m		 /
H
0
8
1		 /
H
0
1
7		 C
h
a
n
g
e
T
l
l
t
o
a
s
a
e
s		 1
7
7		 6
0
1		 %
1
1
i
i
i
B
D
o
n
y
v
s
:
b
P
j
i
t
r
o
e
c
u
s
n
e
s
s
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 9
9
7
8		 8
7
7
3		 %
1
4
7
%
*
O
d
i
k
t
r
e
r
n
a
e		 1
7
0		 8
4		 1
0
2
%
*
d
b
O
k
l
r
e
r
a
c
o
g		 5
7
3		 **
5
1
0		 1
2
%

* project business only ** Dec 31, 2007

Fresenius Vamed: EBIT Development According to Plan

€
m		 /
H
1
0
8		 /
H
1
0
7		 C
h
a
n
g
e
T
l
E
B
I
T
t
o
a
M
i
a
g
n
r		 9
5
1
%		 9
5
6
%		 0
%
i
N
t
e
n
c
o
m
e		 9 8 3
%
1

Fresenius Kabi: Strong Sales Growth in H1/2008

€
m		 /
H
1
0
8		 /
H
1
0
7		 O
i
r
g
a
n
c
G
h
t
r
o
w
S
l
a
e
s		 1
1
2
1
,		 9
8
6		 1
0
%
d
B
P
S
t
t
o
c
e
g
m
e
n
y
r
u
:
f
h
I
i
T
n
s
o
n
e
a
p
u
r
y		 5
8
9		 5
2
9		 6
%
C
l
i
i
l
i
i
N
t
t
n
c
a
u
r
o
n		 6
4
1		 3
9
8		 3
%
1
f
h
l
T
i
T
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 7
1		 9
5		 9
%
1

Fresenius Helios: Performance Indicators

/
H
1
0
8		 /
H
1
0
7		 C
h
a
n
g
e
f
h
l


N
i
t
o
o
o
s
p
a
s
l
A
i
i
t
c
e
c
n
c
s
u
-
l
P
t
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
0
4
0
2
0		 6
0
4
0
2
0
f
b
d


N
o
o
e
s
l
A
t
i
i
c
u
e
c
n
c
s
-
P
l
i
i
t
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
0
1
7
4
,
3,
6
9
9
1
3,
7
6
1		 9
2
1
7
1
,
3,
3
3
3
1
3,
8
5
9		 2
%
3
%
3
%
-
d
*
A
i
i
m
s
s
o
n
s
(
)
A
i
i
t
t
t
c
e
c
a
e
n
p
a
e
n
u
r
-		 2
5
5,
9
2
4		 2
1
1,
5
2
4		 2
1
%
*
O
c
c
p
a
n
c
u
y
P
t
t
o
s
a
c
u
e
c
a
r
e
-		 7
9
%		 8
1
%
l
h
f
(
d
)

A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s

A
t
c
e
c
a
e
u
r
-
*
P
t
t
o
s
a
c
u
e
c
a
r
e
-		 7.
1
3
0.
7		 7.
1
3
9
1.

* Clinics in Germany ** Dec 31, 2007

Fresenius Helios:Sales Impact Hospital Acquisitions

Hospital Mariahilf, Hamburg € ~26 m not yet closed

Acquisitions Annualized sales

  • Hospital Oberhausen (NRW) € ~20 m consolidated as of Apr 1, 2007
  • Hospital Lengerich (NRW) € ~12 m consolidated as of Apr 1, 2007
  • Municipal hospitals, Krefeld and Hüls € ~175 m consolidated as of Dec 31, 2007

Fresenius Group: Key Figures According to IFRS

€
m		 /
H
0
8
1
U
S
G
A
A
P		 /
H
0
8
1
I
F
R
S
l
S
a
e
s		 5
7
1
0
,		 5
7
1
9
,
E
B
I
T		 8
7
1		 7
8
6
l
I
t
t
t
n
e
r
e
s
r
e
s
u		 1
6
7
-		 1
6
7
-
N
i
t
e
n
c
o
m
e		 2
1
2		 2
1
1
h
f
l
O
i
C
t
p
e
a
n
g
a
s
o
r
w		 4
8
1		 4
8
3
l
h
l
B
t
t
t
a
a
n
c
e
s
e
e
o
a		 9
1
5
4
1
,		 3
1
5
5
4
,

Financial Calendar

2
0
0
8
4
1
1		 d
t-
3
R
1
t
s
r
e
p
o
r
o
n		 2
0
0
8
t
q
u
a
r
e
r
s
--------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------

Contact

Birgit Grund SVP Investor Relations Fresenius SE

Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.